+42.7%
CRDO vs GSK
-11.8%
+54.5%
-47.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 6mo.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.5% | -1.0% | -3.5% | -5.3% |
| 7D | -2.4% | -5.4% | +3.1% | -6.2% |
| 30D | -35.3% | -4.6% | -30.7% | -37.2% |
| 3M | -32.6% | -5.1% | -27.4% | -34.4% |
| 6M | +42.7% | -11.4% | +54.1% | +36.0% |
| All | +42.7% | -11.8% | +54.5% | +36.0% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 6mo: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
6mo analysis · Full analysis span regression · 6 months rolling